{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunoglobulin+G&page=9", "query": { "intervention": "Immunoglobulin G", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 882, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunoglobulin+G&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunoglobulin+G&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T12:56:21.730Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04181060", "title": "Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Lung Non-Squamous Non-Small Cell Carcinoma", "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma", "Recurrent Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2020-12-28", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-13T12:56:21.730Z", "location_count": 603, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 425 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04181060" }, { "nct_id": "NCT00719680", "title": "Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Immune Deficiency" ], "interventions": [ { "name": "IgPro20", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "2 Years to 75 Years" }, "enrollment_count": 21, "start_date": "2008-06", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2014-04-02", "last_synced_at": "2026-10-13T12:56:21.730Z", "location_count": 4, "location_summary": "Centennial, Colorado • North Palm Beach, Florida • Indianapolis, Indiana + 1 more", "locations": [ { "city": "Centennial", "state": "Colorado" }, { "city": "North Palm Beach", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00719680" }, { "nct_id": "NCT00822770", "title": "Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stem Cell Transplantation", "Leukemia" ], "interventions": [ { "name": "Plerixafor", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Allogeneic blood stem cell transplant", "type": "PROCEDURE" }, { "name": "ATG (Thymoglobulin)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 47, "start_date": "2009-01", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-10-13T12:56:21.730Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00822770" }, { "nct_id": "NCT00878254", "title": "Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle-Cell Lymphoma" ], "interventions": [ { "name": "G-CSF", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2009-03-25", "completion_date": "2025-05-30", "has_results": true, "last_update_posted_date": "2025-07-23", "last_synced_at": "2026-10-13T12:56:21.730Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00878254" }, { "nct_id": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB0123667", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 291, "start_date": "2022-07-05", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-13T12:56:21.730Z", "location_count": 18, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05238922" }, { "nct_id": "NCT06935266", "title": "A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "TAK-881", "type": "BIOLOGICAL" }, { "name": "SC Investigational Needle Sets", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 64, "start_date": "2025-04-22", "completion_date": "2025-09-27", "has_results": true, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-13T12:56:21.730Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06935266" }, { "nct_id": "NCT02142803", "title": "TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Glioblastoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Malignant Uterine Corpus Neoplasm", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Solid Neoplasm", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2014-05-20", "completion_date": "2026-10-16", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-13T12:56:21.730Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Charlestown, Massachusetts • Columbus, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Charlestown", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02142803" }, { "nct_id": "NCT00000642", "title": "A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "Pregnancy" ], "interventions": [ { "name": "CD4-IgG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "60 Years", "sex": "ALL", "summary": "1 Day to 60 Years" }, "enrollment_count": 30, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-13T12:56:21.730Z", "location_count": 2, "location_summary": "Brooklyn, New York • Houston, Texas", "locations": [ { "city": "Brooklyn", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000642" }, { "nct_id": "NCT00673556", "title": "A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Psoriasis" ], "interventions": [ { "name": "alefacept", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 195, "start_date": "2003-10", "completion_date": "2005-05", "has_results": false, "last_update_posted_date": "2014-08-26", "last_synced_at": "2026-10-13T12:56:21.730Z", "location_count": 10, "location_summary": "Irvine, California • Santa Monica, California • Omaha, Nebraska + 7 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00673556" }, { "nct_id": "NCT00278954", "title": "Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Immunodeficiency", "Common Variable Hypogammaglobulinemia", "X-linked Hypogammaglobulinemia", "Hypogammaglobulinemia", "Immunodeficiency With Hyper-IgM", "Wiskott-Aldrich Syndrome" ], "interventions": [ { "name": "Gammaplex (Intravenous immunoglobulin)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bio Products Laboratory", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 50, "start_date": "2006-01", "completion_date": "2007-11", "has_results": true, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-10-13T12:56:21.730Z", "location_count": 7, "location_summary": "North Palm Beach, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more", "locations": [ { "city": "North Palm Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Buffalo", "state": "New York" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00278954" } ] }